Related Experiment Videos
Gastric inhibitory polypeptide release from a tumor-derived cell line
T J Kieffer1, Z Huang, C H McIntosh
1Department of Physiology, University of British Columbia, Vancouver, Canada.
The American Journal of Physiology
|August 1, 1995
Summary
A new mouse intestinal tumor cell line (STC 6-14) co-expresses gastric inhibitory polypeptide (GIP) and somatostatin (SS). This model allows for studying GIP and SS release and regulation in a controlled environment.
Area of Science:
- Endocrinology
- Cell Biology
- Gastroenterology
Background:
- Gastric inhibitory polypeptide (GIP) and somatostatin (SS) are key gastrointestinal hormones.
- Understanding their co-regulation is crucial for metabolic and digestive research.
Purpose of the Study:
- To establish and characterize a novel cell line co-expressing GIP and SS.
- To investigate the synthesis, storage, and release of GIP and SS from this cell line.
Main Methods:
- Subcloning of the STC-1 mouse intestinal tumor cell line to create STC 6-14.
- High-performance liquid chromatography (HPLC) for peptide identification and quantification.
- Measurement of basal and stimulated release of GIP and SS under varying glucose and peptide concentrations.
Main Results:
- The STC 6-14 cell line stably expressed both immunoreactive GIP (irGIP) and somatostatin (irSS).
- irGIP and irSS exhibited chromatographic behavior consistent with synthetic GIP-(1-42) and SS-(1-14).
- Glucose stimulated GIP release, which was modulated by SS, while glucose and GIP stimulated SS release.
Conclusions:
- The STC 6-14 cell line serves as a valuable in vitro model for studying GIP and SS.
- This model facilitates research into the interplay between GIP and SS synthesis, storage, and release.
- The findings provide insights into the complex regulation of these important gastrointestinal hormones.